![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 4
2024
Wolff, Andreas W.; Bidner, Helen; Remane, Yvonne; Zimmer, Janine; Aarsland, Dag; Rascol, Olivier; Wyse, Richard K.; Hapfelmeier, Alexander und Lingor, Paul
(2024):
Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson's disease (ROCK-PD).
In: Frontiers in Aging Neuroscience, Bd. 16, 1308577
[PDF, 566kB]
Wolff, Andreas W.; Peine, Joerg; Hoefler, Josef; Zurek, Gabriela; Hemker, Claus und Lingor, Paul
(2024):
SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants.
In: Cns Drugs
[PDF, 1MB]
2022
Lingor, Paul; Demleitner, Antonia F.; Wolff, Andreas W. und Feneberg, Emily
(2022):
SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't.
In: Journal of Neural Transmission, Bd. 129, Nr. 9: S. 1155-1167
[PDF, 870kB]
Demleitner, Antonia F.; Wolff, Andreas W.; Erber, Johanna; Gebhardt, Friedemann; Westenberg, Erica; Winkler, Andrea S.; Kolbe-Busch, Susanne; Chaberny, Iris F. und Lingor, Paul
(2022):
Best practice approaches to outpatient management of people living with Parkinson's disease during the COVID-19 pandemic.
In: Journal of Neural Transmission, Bd. 129, Nr. 11: S. 1377-1385
[PDF, 625kB]